Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 74
Filter
1.
Opt Express ; 31(16): 26378-26382, 2023 Jul 31.
Article in English | MEDLINE | ID: mdl-37710500

ABSTRACT

Homodyne detection is a common self-referenced technique to extract optical quadratures. Due to ubiquitous fluctuations, experiments measuring optical quadratures require homodyne angle control. Current homodyne angle locking techniques only provide high quality error signals in a span significantly smaller than π radians, the span required for full state tomography, leading to inevitable discontinuities during full tomography. Here, we present and demonstrate a locking technique using a universally tunable modulator which produces high quality error signals at an arbitrary homodyne angle. Our work enables continuous full-state tomography and paves the way to backaction evasion protocols based on a time-varying homodyne angle.

2.
Front Med (Lausanne) ; 8: 660877, 2021.
Article in English | MEDLINE | ID: mdl-33937296

ABSTRACT

Islet transplantation can restore glycemic control in patients with type 1 diabetes. Using this procedure, the early stages of engraftment are often crucial to long-term islet function, and outcomes are not always successful. Numerous studies have shown that mesenchymal stem cells (MSCs) facilitate islet graft function. However, experimental data can be inconsistent due to variables associated with MSC generation (including donor characteristics and tissue source), thus, demonstrating the need for a well-characterized and uniform cell product before translation to the clinic. Unlike bone marrow- or adipose tissue-derived MSCs, human embryonic stem cell-derived-MSCs (hESC-MSCs) offer an unlimited source of stable and highly-characterized cells that are easily scalable. Here, we studied the effects of human hemangioblast-derived mesenchymal cells (HMCs), (i.e., MSCs differentiated from hESCs using a hemangioblast intermediate), on islet cell transplantation using a minimal islet mass model. The co-transplantation of the HMCs allowed a mass of islets that was insufficient to correct diabetes on its own to restore glycemic control in all recipients. Our in vitro studies help to elucidate the mechanisms including reduction of cytokine stress by which the HMCs support islet graft protection in vivo. Derivation, stability, and scalability of the HMC source may offer unique advantages for clinical applications, including fewer islets needed for successful islet transplantation.

3.
Opt Lett ; 46(8): 1946-1949, 2021 Apr 15.
Article in English | MEDLINE | ID: mdl-33857112

ABSTRACT

This Letter reports the experimental realization of a novel, to the best of our knowledge, active power stabilization scheme in which laser power fluctuations are sensed via the radiation pressure driven motion they induce on a movable mirror. The mirror position and its fluctuations were determined by means of a weak auxiliary laser beam and a Michelson interferometer, which formed the in-loop sensor of the power stabilization feedback control system. This sensing technique exploits a nondemolition measurement, which can result in higher sensitivity for power fluctuations than direct, and hence destructive, detection. Here we used this new scheme in a proof-of-concept experiment to demonstrate power stabilization in the frequency range from 1 Hz to 10 kHz, limited at low frequencies by the thermal noise of the movable mirror at room temperature.

5.
Nat Rev Drug Discov ; 19(7): 463-479, 2020 07.
Article in English | MEDLINE | ID: mdl-32612263

ABSTRACT

Naturally occurring stem cells isolated from humans have been used therapeutically for decades. This has primarily involved the transplantation of primary cells such as haematopoietic and mesenchymal stem cells and, more recently, derivatives of pluripotent stem cells. However, the advent of cell-engineering approaches is ushering in a new generation of stem cell-based therapies, greatly expanding their therapeutic utility. These next-generation stem cells are being used as 'Trojan horses' to improve the delivery of drugs and oncolytic viruses to intractable tumours and are also being engineered with angiogenic, neurotrophic and anti-inflammatory molecules to accelerate the repair of injured or diseased tissues. Moreover, gene therapy and gene editing technologies are being used to create stem cell derivatives with improved functionality, specificity and responsiveness compared with their natural counterparts. Here, we review these engineering approaches and areas in which they will help broaden the utility and clinical applicability of stem cells.


Subject(s)
Cell Engineering/methods , Stem Cell Transplantation/methods , Stem Cells/cytology , Animals , Drug Delivery Systems , Gene Editing , Genetic Therapy/methods , Humans , Oncolytic Virotherapy/methods
6.
Nat Rev Immunol ; 19(12): 723-733, 2019 12.
Article in English | MEDLINE | ID: mdl-31417198

ABSTRACT

The prospect of transplanting cells and tissues without the risk of immune rejection or the need for powerful immunosuppressive drugs is the 'holy grail' of transplantation medicine. Now, with the advent of pluripotent stem cells, CRISPR-Cas9 and other gene-editing technologies, the race to create 'off-the-shelf' donor cells that are invisible to the immune system ('universal cells') has started. One important approach for creating such cells involves the manipulation of genes required for immune recognition, in particular HLA class I and II proteins. Other approaches leverage knowledge of immune-cloaking strategies used by certain bacteria, viruses, parasites, the fetus and cancer cells to induce tolerance to allogeneic cell-based therapies by modifying cells to express immune-suppressive molecules such as PD-L1 and CTLA4-Ig. Various academic groups as well as biotechnology and pharmaceutical companies are on the verge of bringing these therapies into the clinic.


Subject(s)
Genetic Engineering , Histocompatibility Antigens Class II/genetics , Histocompatibility Antigens Class I/genetics , Immune Evasion , Animals , Female , Humans , Neoplasms/immunology , Placenta/immunology , Pregnancy , Stem Cell Transplantation
7.
Nature ; 568(7752): 364-367, 2019 04.
Article in English | MEDLINE | ID: mdl-30911169

ABSTRACT

Quantum mechanics places a fundamental limit on the precision of continuous measurements. The Heisenberg uncertainty principle dictates that as the precision of a measurement of an observable (for example, position) increases, back action creates increased uncertainty in the conjugate variable (for example, momentum). In interferometric gravitational-wave detectors, higher laser powers reduce the position uncertainty created by shot noise (the photon-counting error caused by the quantum nature of the laser) but necessarily do so at the expense of back action in the form of quantum radiation pressure noise (QRPN)1. Once at design sensitivity, the gravitational-wave detectors Advanced LIGO2, VIRGO3 and KAGRA4 will be limited by QRPN at frequencies between 10 hertz and 100 hertz. There exist several proposals to improve the sensitivity of gravitational-wave detectors by mitigating QRPN5-10, but until now no platform has allowed for experimental tests of these ideas. Here we present a broadband measurement of QRPN at room temperature at frequencies relevant to gravitational-wave detectors. The noise spectrum obtained shows effects due to QRPN between about 2 kilohertz and 100 kilohertz, and the measured magnitude of QRPN agrees with our model. We now have a testbed for studying techniques with which to mitigate quantum back action, such as variational readout and squeezed light injection7, with the aim of improving the sensitivity of future gravitational-wave detectors.

8.
Ophthalmology ; 125(11): 1765-1775, 2018 11.
Article in English | MEDLINE | ID: mdl-29884405

ABSTRACT

PURPOSE: Transplantation of human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells offers the potential for benefit in macular degeneration. Previous trials have reported improved visual acuity (VA), but lacked detailed analysis of retinal structure and function in the treated area. DESIGN: Phase 1/2 open-label dose-escalation trial to evaluate safety and potential efficacy (clinicaltrials.gov identifier, NCT01469832). PARTICIPANTS: Twelve participants with advanced Stargardt disease (STGD1), the most common cause of macular degeneration in children and young adults. METHODS: Subretinal transplantation of up to 200 000 hESC-derived RPE cells with systemic immunosuppressive therapy for 13 weeks. MAIN OUTCOME MEASURES: The primary end points were the safety and tolerability of hESC-derived RPE cell administration. We also investigated evidence of the survival of transplanted cells and measured retinal structure and function using microperimetry and spectral-domain OCT. RESULTS: Focal areas of subretinal hyperpigmentation developed in all participants in a dose-dependent manner in the recipient retina and persisted after withdrawal of systemic immunosuppression. We found no evidence of uncontrolled proliferation or inflammatory responses. Borderline improvements in best-corrected VA in 4 participants either were unsustained or were matched by a similar improvement in the untreated contralateral eye. Microperimetry demonstrated no evidence of benefit at 12 months in the 12 participants. In one instance at the highest dose, localized retinal thinning and reduced sensitivity in the area of hyperpigmentation suggested the potential for harm. Participant-reported quality of life using the 25-item National Eye Institute Visual Function Questionnaire indicated no significant change. CONCLUSIONS: Subretinal hyperpigmentation is consistent with the survival of viable transplanted hESC-derived RPE cells, but may reflect released pigment in their absence. The findings demonstrate the value of detailed analysis of spatial correlation of retinal structure and function in determining with appropriate sensitivity the impact of cell transplantation and suggest that intervention in early stage of disease should be approached with caution. Given the slow rate of progressive degeneration at this advanced stage of disease, any protection against further deterioration may be evident only after a more extended period of observation.


Subject(s)
Human Embryonic Stem Cells/transplantation , Macular Degeneration/congenital , Retinal Pigment Epithelium/transplantation , Adult , Electroretinography , Female , Fluorescein Angiography , Humans , Immunosuppressive Agents/therapeutic use , Macular Degeneration/diagnostic imaging , Macular Degeneration/physiopathology , Macular Degeneration/therapy , Male , Middle Aged , Photoreceptor Cells, Vertebrate/physiology , Quality of Life , Sickness Impact Profile , Slit Lamp Microscopy , Stargardt Disease , Tomography, Optical Coherence , Visual Acuity/physiology , Visual Field Tests , Visual Fields/physiology
9.
Ocul Immunol Inflamm ; 26(8): 1228-1236, 2018.
Article in English | MEDLINE | ID: mdl-28914568

ABSTRACT

PURPOSE: We investigated the effect of exogenously administered human embryonic stem cell-derived mesenchymal stromal cells (hESC-MSCs) in experimental autoimmune uveitis (EAU) in B10.RIII mice, a murine model of severe uveitis. METHODS: B10.RIII mice were immunized with an uveitogenic peptide, and intraperitoneal injections of 5 million hESC-MSCs per animal were given on the same day. Behavioral light sensitivity assays, histological evaluation, cytokine production, and regulatory T cells were analyzed at the peak of the disease. RESULTS: Histological and behavioral evidence demonstrated that early systemic treatment with hESC-MSCs decreases the development of severe EAU in B10.RIII mice. hESC-MSCs suppress Th17 and upregulate Th1 and Th2 responses as well as IL-2 and GM-CSF in splenocytes from hESC-MSC-treated mice. CONCLUSIONS: MSCs that originate from hESC decrease the development of severe EAU in B10.RIII mice, likely through systemic immune modulation. Further investigation is needed to determine any potential effect on active EAU.


Subject(s)
Autoimmune Diseases/prevention & control , Human Embryonic Stem Cells/cytology , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/physiology , Stromal Cells/physiology , Uveitis/prevention & control , Animals , Autoimmune Diseases/immunology , Cytokines/metabolism , Disease Models, Animal , Female , Flow Cytometry , Humans , Mice , Th1 Cells/immunology , Th17 Cells/immunology , Th2 Cells/immunology , Uveitis/immunology
10.
Acta Ophthalmol ; 95(6): e468-e476, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28636206

ABSTRACT

OBJECTIVE: To investigate whether intravitreally applied haemangioblasts (HB) derived from human embryonic stem cells (hESCs) are helpful for the repair of vascular damage caused in animals by an oxygen-induced retinopathy (OIR), by an induced diabetic retinopathy (DR) or by an induced retinal ischaemia with subsequent reperfusion. METHODS: Human embryonic stem cell-derived HBs were transplanted intravitreally into C57BL/6J mice (OIR model), into male Wistar rats with an induced DR and into male Wistar rats undergoing induced retinal ischaemia with subsequent reperfusion. Control groups of animals received an intravitreal injection of endothelial cells (ECs) or phosphate-buffered saline (PBS). We examined the vasculature integrity in the mice with OIR, the blood-retina barrier in the rats with induced DR, and retinal thickness and retinal ganglion cell density in retina flat mounts of the rats with the retinal ischaemic-reperfusion retinopathy. RESULTS: In the OIR model, the study group versus control groups showed a significantly (p < 0.001) smaller retinal avascular area [5.1 ± 2.7%;n = 18 animals versus 12.2 ± 2.8% (PBS group; n = 10 animals) and versus 11.8 ± 3.7% (EC group; n = 8 animals)] and less retinal neovascularization [6.3 ± 2.5%;n = 18 versus 15.2 ± 6.3% (n = 10; PBS group) and versus 15.8 ± 3.3% (n = 8; EC group)]. On retinal flat mounts, hESC-HBs were integrated into damaged retinal vessels and stained positive for PECAM (CD31) as EC marker. In the DR model, the study group versus the EC control group showed a significantly (p = 0.001) better blood-retina barrier function as measured at 2 days after the intravitreal injections [study group: 20.2 ± 12.8 µl/(g × hr); n = 6; versus EC control group: 52.9 ± 9.9 µl/(g × hr; n = 6)]. In the retinal ischaemia-reperfusion model, the groups did not differ significantly in retinal thickness and retinal ganglion cell density at 2, 5 and 7 days after baseline. CONCLUSION: By integrating into damaged retinal vessels and differentiating into ECs, intravitreally administered hESC-HBs may have partially repaired a retinal vascular injury caused by OIR model and DR.


Subject(s)
Embryonic Stem Cells/transplantation , Hemangioblasts/transplantation , Retinal Diseases/surgery , Stem Cell Transplantation/methods , Animals , Cells, Cultured , Disease Models, Animal , Humans , Intravitreal Injections , Male , Mice , Mice, Inbred C57BL , Oxygen/toxicity , Rats , Rats, Wistar , Reperfusion Injury/complications , Retinal Diseases/etiology , Retinal Diseases/pathology , Retinal Vessels/pathology
11.
Regen Med ; 11(8): 831-847, 2016 12.
Article in English | MEDLINE | ID: mdl-27908220

ABSTRACT

Pluripotent stem cells (PSCs) can differentiate into virtually any cell type in the body, making them attractive for both regenerative medicine and drug discovery. Over the past 10 years, technological advances and innovative platforms have yielded first-in-man PSC-based clinical trials and opened up new approaches for disease modeling and drug development. Induced PSCs have become the foremost alternative to embryonic stem cells and accelerated the development of disease-in-a-dish models. Over the years and with each new discovery, PSCs have proven to be extremely versatile. This review article highlights key advancements in PSC research, from 2006 to 2016, and how they will guide the direction of the field over the next decade.


Subject(s)
Pluripotent Stem Cells/cytology , Regenerative Medicine , Stem Cell Transplantation , Tissue Engineering/methods , Animals , Humans
13.
Phys Rev Lett ; 117(11): 111102, 2016 Sep 09.
Article in English | MEDLINE | ID: mdl-27661676

ABSTRACT

Measurements are reported of the cross-correlation of spectra of differential position signals from the Fermilab Holometer, a pair of colocated 39 m long, high power Michelson interferometers with flat broadband frequency response in the MHz range. The instrument obtains sensitivity to high frequency correlated signals far exceeding any previous measurement in a broad frequency band extending beyond the 3.8 MHz inverse light-crossing time of the apparatus. The dominant but uncorrelated shot noise is averaged down over 2×10^{8} independent spectral measurements with 381 Hz frequency resolution to obtain 2.1×10^{-20}m/sqrt[Hz] sensitivity to stationary signals. For signal bandwidths Δf>11 kHz, the sensitivity to strain h or shear power spectral density of classical or exotic origin surpasses a milestone PSD_{δh}

14.
Sci Rep ; 6: 29784, 2016 07 13.
Article in English | MEDLINE | ID: mdl-27405580

ABSTRACT

Photoreceptor degeneration due to retinitis pigmentosa (RP) is a primary cause of inherited retinal blindness. Photoreceptor cell-replacement may hold the potential for repair in a completely degenerate retina by reinstating light sensitive cells to form connections that relay information to downstream retinal layers. This study assessed the therapeutic potential of photoreceptor progenitors derived from human embryonic and induced pluripotent stem cells (ESCs and iPSCs) using a protocol that is suitable for future clinical trials. ESCs and iPSCs were cultured in four specific stages under defined conditions, resulting in generation of a near-homogeneous population of photoreceptor-like progenitors. Following transplantation into mice with end-stage retinal degeneration, these cells differentiated into photoreceptors and formed a cell layer connected with host retinal neurons. Visual function was partially restored in treated animals, as evidenced by two visual behavioral tests. Furthermore, the magnitude of functional improvement was positively correlated with the number of engrafted cells. Similar efficacy was observed using either ESCs or iPSCs as source material. These data validate the potential of human pluripotent stem cells for photoreceptor replacement therapies aimed at photoreceptor regeneration in retinal disease.


Subject(s)
Blindness , Cell Differentiation , Human Embryonic Stem Cells , Induced Pluripotent Stem Cells , Photoreceptor Cells, Vertebrate , Retinitis Pigmentosa , Animals , Blindness/metabolism , Blindness/pathology , Blindness/therapy , Heterografts , Human Embryonic Stem Cells/metabolism , Human Embryonic Stem Cells/pathology , Humans , Induced Pluripotent Stem Cells/metabolism , Induced Pluripotent Stem Cells/pathology , Mice , Photoreceptor Cells, Vertebrate/metabolism , Photoreceptor Cells, Vertebrate/pathology , Photoreceptor Cells, Vertebrate/transplantation , Retinitis Pigmentosa/metabolism , Retinitis Pigmentosa/pathology , Retinitis Pigmentosa/therapy
15.
Regen Med ; 11(1): 33-43, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26387424

ABSTRACT

AIM: To evaluate the safety and efficacy of intralesional injection of human embryonic stem cell (hESC)-derived mesenchymal stem/stromal cells (MSCs) in canine anal furunculosis dogs. MATERIALS & METHODS: Dogs naturally develop an immune-mediated disease called canine anal furunculosis, which shares many features with human fistulizing Crohn's disease. RESULTS: The hESC-MSCs were well tolerated and 1 month postinjection, accompanied by reduced serum levels of IL-2 and IL-6, two inflammatory cytokines associated with Crohn's disease. All six dogs were found to be completely free of fistulas at 3 months postinjection. However, at 6 months, two dogs had some fistula relapse. CONCLUSION: Results of this study provide the first evidence of the safety and therapeutic potential of hESC-MSCs in a large animal model.


Subject(s)
Crohn Disease/therapy , Human Embryonic Stem Cells/cytology , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/cytology , Rectal Fistula/therapy , Animals , Crohn Disease/drug therapy , Cyclosporine/pharmacology , Cyclosporine/therapeutic use , Cytokines/blood , Disease Models, Animal , Dogs , Dose-Response Relationship, Drug , Follow-Up Studies , Heterografts , Humans , Immunomodulation , Stromal Cells/cytology
16.
PLoS One ; 10(12): e0145266, 2015.
Article in English | MEDLINE | ID: mdl-26689688

ABSTRACT

AIM: To generate human embryonic stem cell derived corneal endothelial cells (hESC-CECs) for transplantation in patients with corneal endothelial dystrophies. MATERIALS AND METHODS: Feeder-free hESC-CECs were generated by a directed differentiation protocol. hESC-CECs were characterized by morphology, expression of corneal endothelial markers, and microarray analysis of gene expression. RESULTS: hESC-CECs were nearly identical morphologically to primary human corneal endothelial cells, expressed Zona Occludens 1 (ZO-1) and Na+/K+ATPaseα1 (ATPA1) on the apical surface in monolayer culture, and produced the key proteins of Descemet's membrane, Collagen VIIIα1 and VIIIα2 (COL8A1 and 8A2). Quantitative PCR analysis revealed expression of all corneal endothelial pump transcripts. hESC-CECs were 96% similar to primary human adult CECs by microarray analysis. CONCLUSION: hESC-CECs are morphologically similar, express corneal endothelial cell markers and express a nearly identical complement of genes compared to human adult corneal endothelial cells. hESC-CECs may be a suitable alternative to donor-derived corneal endothelium.


Subject(s)
Cell Differentiation , Cornea/metabolism , Endothelial Cells/metabolism , Human Embryonic Stem Cells/metabolism , Collagen Type VIII/biosynthesis , Cornea/cytology , Endothelial Cells/cytology , Human Embryonic Stem Cells/cytology , Humans , Sodium-Potassium-Exchanging ATPase/biosynthesis , Zonula Occludens-1 Protein/biosynthesis
17.
Sci Rep ; 5: 17685, 2015 Dec 02.
Article in English | MEDLINE | ID: mdl-26628350

ABSTRACT

Adult tissue-derived mesenchymal stromal cells (MSCs) are showing promise in clinical trials for systemic lupus erythematosus (SLE). However, the inability to manufacture large quantities of functional cells from a single donor as well as donor-dependent variability in quality limits their clinical utility. Human embryonic stem cell (hESC)-derived MSCs are an alternative to adult MSCs that can circumvent issues regarding scalability and consistent quality due to their derivation from a renewable starting material. Here, we show that hESC-MSCs prevent the progression of fatal lupus nephritis (LN) in NZB/W F1 (BWF1) mice. Treatment led to statistically significant reductions in proteinuria and serum creatinine and preserved renal architecture. Specifically, hESC-MSC treatment prevented disease-associated interstitial inflammation, protein cast deposition, and infiltration of CD3(+) lymphocytes in the kidneys. This therapy also led to significant reductions in serum levels of tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6), two inflammatory cytokines associated with SLE. Mechanistically, in vitro data support these findings, as co-culture of hESC-MSCs with lipopolysaccharide (LPS)-stimulated BWF1 lymphocytes decreased lymphocyte secretion of TNFα and IL-6, and enhanced the percentage of putative regulatory T cells. This study represents an important step in the development of a commercially scalable and efficacious cell therapy for SLE/LN.


Subject(s)
Human Embryonic Stem Cells/metabolism , Kidney , Lupus Nephritis , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/metabolism , Adult Stem Cells/metabolism , Animals , Disease Models, Animal , Heterografts , Humans , Kidney/metabolism , Kidney/pathology , Kidney/physiopathology , Lupus Nephritis/metabolism , Lupus Nephritis/pathology , Lupus Nephritis/physiopathology , Lupus Nephritis/therapy , Mice
18.
Nat Rev Drug Discov ; 14(10): 681-92, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26391880

ABSTRACT

Pluripotent stem cells (PSCs) hold great promise for drug discovery and regenerative medicine owing to their ability to differentiate into any cell type in the body. After more than three decades of research, including delays due to the potential tumorigenicity of PSCs and inefficiencies in differentiation methods, the field is at a turning point, with a number of clinical trials across the globe now testing PSC-derived products in humans. Ocular diseases dominate these first-in-man trials, and Phase l/ll results are showing promising safety data as well as possible efficacy. In addition, the advent of induced PSC (iPSC) technology is enabling the development of a wide range of cell-based disease models from genetically predisposed patients, thereby facilitating drug discovery. In this Review, we discuss the recent progress and remaining challenges for the use of PSCs in regenerative medicine and drug development.


Subject(s)
Drug Discovery , Pluripotent Stem Cells/transplantation , Regenerative Medicine , Clinical Trials as Topic , Heart Diseases/therapy , Humans , Lung Diseases/therapy , Macular Degeneration/therapy , Neurodegenerative Diseases/therapy , Retinal Pigment Epithelium/transplantation
20.
Stem Cell Reports ; 4(5): 860-72, 2015 May 12.
Article in English | MEDLINE | ID: mdl-25937371

ABSTRACT

Embryonic stem cells hold great promise for various diseases because of their unlimited capacity for self-renewal and ability to differentiate into any cell type in the body. However, despite over 3 decades of research, there have been no reports on the safety and potential efficacy of pluripotent stem cell progeny in Asian patients with any disease. Here, we report the safety and tolerability of subretinal transplantation of human embryonic-stem-cell (hESC)-derived retinal pigment epithelium in four Asian patients: two with dry age-related macular degeneration and two with Stargardt macular dystrophy. They were followed for 1 year. There was no evidence of adverse proliferation, tumorigenicity, ectopic tissue formation, or other serious safety issues related to the transplanted cells. Visual acuity improved 9-19 letters in three patients and remained stable (+1 letter) in one patient. The results confirmed that hESC-derived cells could serve as a potentially safe new source for regenerative medicine.


Subject(s)
Embryonic Stem Cells/cytology , Macular Degeneration/therapy , Retinal Pigment Epithelium/transplantation , Aged , Asian People , Cell Differentiation , Electroretinography , Female , Humans , Macular Degeneration/congenital , Male , Middle Aged , Retinal Pigment Epithelium/cytology , Retinal Pigment Epithelium/metabolism , Stargardt Disease , Visual Acuity
SELECTION OF CITATIONS
SEARCH DETAIL
...